The statistic functions view organizes Pearson Correlation Coefficient function and supporting indicators around Foghorn Therapeutics. The analysis highlights statistical functions describing dispersion and variability and frames technical signals with volatility and risk context.Select Time Period to execute this module.
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Pearsons Correlation Coefficient is one of the most common measures of correlation in financial statistics. It shows the linear relationship between price series of Foghorn Therapeutics and its benchmark or peer.
Foghorn Therapeutics Technical Analysis Modules
Most technical analysis of Foghorn Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Foghorn from various momentum indicators to cycle indicators. When you analyze Foghorn charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Foghorn Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. Downside history and drawdown behavior provide context for risk expectations in Foghorn Therapeutics. Past price movements indicate comparatively limited downside dispersion. Foghorn Therapeutics has a market cap of 288.22 M, ROE of -4.7%.
Methodology
Unless otherwise specified, financial data for Foghorn Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Foghorn (USA Stocks:FHTX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Foghorn Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Foghorn Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Foghorn Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
A structured review of Foghorn Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Foghorn Therapeutics Stock. Highlighted below are reports that provide context for Foghorn Therapeutics Stock:
Foghorn Therapeutics has a market cap of 288.22 M, operating margin of -2.12%, ROE of -4.7%. Investing Opportunities can help frame allocation decisions. The allocation includes a position in Foghorn Therapeutics inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Explore our How to Trade Foghorn Stock guide to learn how to trade Foghorn Therapeutics effectively.Analysis related to Foghorn Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Market capitalization and book value offer complementary views of Foghorn Therapeutics — the first driven by investor sentiment, the second by accounting standards. Foghorn Therapeutics' market capitalization is 288.22 M. With a P/B ratio of 10.71, the market values Foghorn Therapeutics well above its book equity. Enterprise value stands at 131.64 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Foghorn Therapeutics are related but not identical, and they can diverge across cycles. For Foghorn Therapeutics, key inputs include a P/B ratio of 10.71, a profit margin of -2.4%, ROE of -4.7%, and revenue of 30.91 M. By contrast, market price reflects the level where buyers and sellers transact.